Given the period during which patients were enrolled in this study, potential biomarkers for ICI response such as interferon-γ-related signatures34 or melanoma-based nomograms35, as well as certain immune evasion-related gene alterations (e.g., B2M alteration), could not be incorporated. The gene discussed is B2M; the disease is melanoma.